Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35,687 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants.
Wu LS, Hu Y, Gane EJ, Slaets L, De Creus A, Ding Y, Niu J, Schwabe C, Goeyvaerts N, Xu Z, Huo D, Tuefferd M, Verbrugge I, Van Remoortere P, Schwertschlag U, Vandenbossche J. Wu LS, et al. Among authors: xu z. Antivir Ther. 2023 Feb;28(1):13596535231151626. doi: 10.1177/13596535231151626. Antivir Ther. 2023. PMID: 36691849 Free article.
Pharmacokinetics, safety, and tolerability of TQC3564, a novel CRTh2 receptor antagonist: report of the first-in-human single- and multiple-dose escalation trials in healthy Chinese subjects.
Li X, Li Q, Ji T, Zhang H, Liu J, Wu M, Chen H, Lou J, Liu C, Xu Z, Ding Y. Li X, et al. Among authors: xu z. Expert Opin Investig Drugs. 2022 Jul;31(7):729-736. doi: 10.1080/13543784.2022.2078192. Epub 2022 May 18. Expert Opin Investig Drugs. 2022. PMID: 35574691 Clinical Trial.
Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study.
Xu J, Zhang H, Chen H, Zhu X, Jia H, Xu Z, Huo D, Zhang H, Li C, Ding Y. Xu J, et al. Among authors: xu z. Ann Med. 2023;55(2):2264850. doi: 10.1080/07853890.2023.2264850. Epub 2023 Dec 10. Ann Med. 2023. PMID: 38071661 Free PMC article. Clinical Trial.
A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects.
Liu G, Xu Z, Yang W, Xue J, Wang Y, Liu Z, Cui Y, Qu X, Chang T, Yu S, Cheng Y, Zhou Y, Chen J, Ren Q, Wang W, Deng Q, Wang Z, Yang H. Liu G, et al. Among authors: xu z. Expert Opin Biol Ther. 2022 Feb;22(2):187-195. doi: 10.1080/14712598.2021.1988567. Epub 2021 Oct 18. Expert Opin Biol Ther. 2022. PMID: 34607519 Clinical Trial.
Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial.
Xu Z, Liu Z, Wang Y, Xue J, Chang T, Cui Y, Cheng Y, Liu G, Wang W, Zhou Y, Yu S, Ren Q, Yang W, Qu X, Chen J, Chen X, Deng Q, Yang H, Wang X. Xu Z, et al. Expert Rev Clin Pharmacol. 2023 Apr;16(4):363-370. doi: 10.1080/17512433.2023.2188192. Epub 2023 Mar 8. Expert Rev Clin Pharmacol. 2023. PMID: 36883362 Clinical Trial.
35,687 results
You have reached the last available page of results. Please see the User Guide for more information.